NCT03123939 - Phase III B in Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

October 13, 2020

Study Completion Date

October 13, 2020

Conditions

Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

CTL019

CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10\^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg)

Trial Locations (11)

9000

Novartis Investigative Site, Ghent

20900

Novartis Investigative Site, Monza

60590

Novartis Investigative Site, Frankfurt

75019

Novartis Investigative Site, Paris

75475

Novartis Investigative Site, Paris

A 1090

Novartis Investigative Site, Vienna

M5G 1X8

Novartis Investigative Site, Toronto

H3T 1C5

Novartis Investigative Site, Montreal

606 8507

Novartis Investigative Site, Kyoto

0424

Novartis Investigative Site, Oslo

08950

Novartis Investigative Site, Esplugues de Llobregat